Fortress Biotech Inc - Company Profile
Powered by 
All the data and insights you need on Fortress Biotech Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Fortress Biotech Inc Strategy Report
- Understand Fortress Biotech Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Fortress Biotech Catalyst Calendar
Proactively evaluate Fortress Biotech Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Fortress Biotech Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Dec 2019 | Phase I Trial Results | City of Hope; Mustang Bio Inc; National Cancer Institute US | MBIO | MB-102 | Oncology | Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia); Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Natural Killer Cell Lymphomas; Plasma Cell Neoplasm; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Company Presentation |
| 01 Dec 2019 | Phase III Trial Initiation | Checkpoint Therapeutics Inc | CKPT | cosibelimab | Oncology | Skin Cancer; Squamous Cell Carcinoma | Company Presentation |
| 28 Sep 2019 | Phase I Trial Results | Checkpoint Therapeutics Inc; Novotech Australia Pty Ltd; Pivotal SL | CKPT | cosibelimab | Oncology | Bladder Cancer; Blood Cancer; Colorectal Cancer; Endometrial Cancer; Head And Neck Cancer; Hematological Tumor; Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Laryngeal Cancer; Lung Cancer; Malignant Mesothelioma; Malignant Pleural Mesothelioma; Melanoma; Merkel Cell Carcinoma; Metastatic Colorectal Cancer; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Metastatic Transitional (Urothelial) Tract Cancer; Non-Hodgkin Lymphoma; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Oral Cavity (Mouth) Cancer; Pharyngeal Neoplasm; Recurrent Head And Neck Cancer Squamous Cell Carcinoma; Renal Cell Carcinoma; Small-Cell Lung Cancer; Squamous Cell Carcinoma; Ureter Cancer; Urethral Cancer | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer